![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AGAP1 |
Gene summary for AGAP1 |
![]() |
Gene information | Species | Human | Gene symbol | AGAP1 | Gene ID | 116987 |
Gene name | ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 | |
Gene Alias | AGAP-1 | |
Cytomap | 2q37.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B2RZG9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116987 | AGAP1 | CCI_1 | Human | Cervix | CC | 9.08e-05 | 7.93e-01 | 0.528 |
116987 | AGAP1 | CCI_3 | Human | Cervix | CC | 1.94e-20 | 1.38e+00 | 0.516 |
116987 | AGAP1 | CCII_1 | Human | Cervix | CC | 6.51e-07 | 4.18e-01 | 0.3249 |
116987 | AGAP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.32e-35 | 1.11e+00 | -0.1954 |
116987 | AGAP1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.59e-13 | 8.34e-01 | -0.2602 |
116987 | AGAP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.09e-06 | 4.70e-01 | -0.2196 |
116987 | AGAP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.34e-07 | 5.26e-01 | -0.1526 |
116987 | AGAP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.59e-09 | 5.64e-01 | -0.1464 |
116987 | AGAP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.34e-10 | 6.08e-01 | -0.1001 |
116987 | AGAP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.57e-05 | 6.17e-01 | -0.059 |
116987 | AGAP1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 9.02e-03 | 2.84e-01 | -0.1706 |
116987 | AGAP1 | HTA11_546_2000001011 | Human | Colorectum | AD | 5.43e-12 | 7.41e-01 | -0.0842 |
116987 | AGAP1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 9.91e-05 | 4.57e-01 | 0.0446 |
116987 | AGAP1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 4.56e-04 | -6.56e-01 | 0.0451 |
116987 | AGAP1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 3.40e-15 | 6.37e-01 | 0.0131 |
116987 | AGAP1 | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.79e-04 | 3.79e-01 | -0.0177 |
116987 | AGAP1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.91e-05 | 3.99e-01 | 0.0588 |
116987 | AGAP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.04e-03 | -3.45e-01 | 0.294 |
116987 | AGAP1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 7.65e-24 | 1.07e+00 | 0.3487 |
116987 | AGAP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.99e-07 | -4.60e-01 | 0.3005 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa0414420 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa04144110 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa0414424 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0414434 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414423 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
hsa0414433 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AGAP1 | SNV | Missense_Mutation | rs376727493 | c.1936N>A | p.Glu646Lys | p.E646K | Q9UPQ3 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
AGAP1 | SNV | Missense_Mutation | novel | c.2264N>A | p.Gly755Asp | p.G755D | Q9UPQ3 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
AGAP1 | SNV | Missense_Mutation | novel | c.451A>C | p.Ser151Arg | p.S151R | Q9UPQ3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGAP1 | SNV | Missense_Mutation | novel | c.2324N>C | p.Leu775Pro | p.L775P | Q9UPQ3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGAP1 | SNV | Missense_Mutation | rs372718570 | c.508G>A | p.Glu170Lys | p.E170K | Q9UPQ3 | protein_coding | deleterious(0) | benign(0.303) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
AGAP1 | SNV | Missense_Mutation | novel | c.1049N>G | p.Gln350Arg | p.Q350R | Q9UPQ3 | protein_coding | deleterious(0.01) | benign(0.115) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
AGAP1 | SNV | Missense_Mutation | rs750448988 | c.922C>T | p.Arg308Cys | p.R308C | Q9UPQ3 | protein_coding | tolerated(0.08) | benign(0.006) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AGAP1 | SNV | Missense_Mutation | novel | c.743A>T | p.Asn248Ile | p.N248I | Q9UPQ3 | protein_coding | deleterious(0) | benign(0.403) | TCGA-EY-A1GF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGAP1 | SNV | Missense_Mutation | rs558257856 | c.1766N>T | p.Ala589Val | p.A589V | Q9UPQ3 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGAP1 | SNV | Missense_Mutation | novel | c.1785N>C | p.Glu595Asp | p.E595D | Q9UPQ3 | protein_coding | tolerated(0.09) | possibly_damaging(0.779) | TCGA-EY-A212-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |